Dopaminergic and non-dopaminergic effects on instrumented timed up and go test in patients with Parkinson’s disease
Objective: To evaluate an instrumented version of Timed Up and Go Test (iTUG) in patients with Parkinson's disease (PD), both in L-dopa OFF and ON-state.…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Healthcare burden of Parkinson’s disease
Objective: Evaluate healthcare costs for a cross-section of patients with Parkinson's disease (PD). Background: PD is a progressive, nonfatal condition with an increasing societal cost…Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease
Objective: The aim of this study was to investigate effects of dophaminergic therapy on olfaction of patients with Parkinson's disease. Background: Influence of dopaminergic drugs…In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves
Objective: Idiopathic Parkinson's disease (IPD) is a chronic neurodegenerative disorder. Most of the clinicians believe that it is limited with motor and cognitive disorders. However,…An atypical case of adult-onset, levodopa-responsive, paroxysmal dystonia
Objective: To describe a case of adult-onset, levodopa-responsive, paroxysmal dystonia. Background: Adult-onset dystonia cases account for at least 90% of primary dystonia, however, less than…The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study
Objective: To examine whether the response to an inhaled levodopa formulation (CVT-301; at 35 and 50 mg per dose) is dependent on baseline patient characteristics.…Characterization of burning mouth syndrome in patients with Parkinson’s disease
Objective: To determine the prevalence and characteristics of burning mouth syndrome (BMS) in a Parkinson's disease (PD) population through a self-administered survey. Background: The majority…Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms
Objective: We investigated whether intrastriatal injection of ionomycin to hemiParkinsonian rats produced changes in L-DOPA responses including LID and analyzed the effects of ionomycin on…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 57
- Next Page »